MHRA issues new batch of Drug Safety Update notices

MHRA issues new batch of Drug Safety Update notices

November 28 2017 The medicines regulator has issued four Drug Safety Updates relating to...

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

November 27 2017 NHS Scotland has updated its recommendations around vitamin D intake for new...

Numbers of people with heart failure diagnoses is up 23% since 2002

Numbers of people with heart failure diagnoses is up 23% since 2002

November 24 2017 There has been a 23% increase in heart failure patients since 2002, the British...

Doxycycline should not normally be used for STI post-exposure prophylaxis

Doxycycline should not normally be used for STI post-exposure prophylaxis

November 10 2017 Doxycycline should not be used for post-exposure prophylaxis (PEP) for sexually...

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

October 31 2017 The medicines regulator has issued four drug safety updates (DRU) relating to...

  • MHRA issues new batch of Drug Safety Update notices

    MHRA issues new batch of Drug Safety Update notices

    Tuesday, 28 November 2017 09:52
  • Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Monday, 27 November 2017 14:50
  • Numbers of people with heart failure diagnoses is up 23% since 2002

    Numbers of people with heart failure diagnoses is up 23% since 2002

    Friday, 24 November 2017 13:06
  • Doxycycline should not normally be used for STI post-exposure prophylaxis

    Doxycycline should not normally be used for STI post-exposure prophylaxis

    Friday, 10 November 2017 17:31
  • MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    Tuesday, 31 October 2017 20:27

drugalertJune 29 2016

Adempas (riociguat) should not be used in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia or PH-IIP, the European Medicines Agency has warned.

Although the drug is not authorised for use in PH-IIP patients, the EMA has issued the recommendation following the early termination of a phase II clinical trial, RISE-IIP, investigating the effects of Adempas in this patient population.

“Preliminary results showed an increased number of deaths and serious adverse events, including breathing problems and lung infections, with Adempas compared with placebo. The available data do not indicate a clinically significant benefit from Adempas treatment in these patients,” said the EMA’s announcement, published on June 24.

The trial had been assessing the medicine in 145 PH-IIP patients, with the primary endpoint being the change in the 6-minute walking distance test after 6 months of treatment. “At the time of the interim assessment leading to the termination of the trial, 21 deaths had been observed, 17 patients taking Adempas and 4 patients taking placebo. Serious adverse events, which were mostly respiratory disease or lung infections, were also higher among patients taking Adempas.”

EMA is advising health professionals that “if any patients with PH-IIP are being treated with Adempas, this treatment should be discontinued and the patient’s clinical status carefully monitored.” A contraindication will also be included in prescribing information, and EMA will be issuing a letter to health professionals. 

It has also stated that Adempas continues to have a positive benefit-risk balance for its authorised uses.

The product’s indications in the UK are:

  • treating adults with WHO Functional Class (FC) II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity
  • as monotherapy or in combination with endothelin receptor antagonists for adults with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.

Links:

EMA announcement

Adempas SPC on eMC

Clinical News

December 7 2017 A new online resource addressing productive healthy ageing and musculoskeletal (MSK) health has been published by Public Health England.
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...